-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Global Medical Marijuana Market Forecast to 2028 - Featuring Aphria, Canopy Growth, CanaQuest Medical and GW Pharmaceuticals Among Others - ResearchAndMarkets.com
Global Medical Marijuana Market Forecast to 2028 - Featuring Aphria, Canopy Growth, CanaQuest Medical and GW Pharmaceuticals Among Others - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Medical Marijuana Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Application, Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering.
The medical marijuana market was valued at US$ 11,706.50 million in 2021 and is likely to reach value of US$ 40,027.59 million by 2028; it is estimated to grow at a CAGR of 19.2% from 2022 to 2028.
The report highlights trends prevailing in the market and factors driving the medical marijuana market. The market growth is attributed to increasing approvals of medical marijuana products and rising acceptance of the medicinal use of marijuana. However, the illegal use of cannabis as a street drug and misconceptions regarding marijuana limit the market growth.
Medical marijuana is in its introduction stage in the medical health industry. It is a potent product accepted globally, where Chinese medicines are already being manufactured using these plants, and that too with a long history associated. Medical marijuana remains a significant influence in the healthcare industry to treat cases that are not entirely advisable with traditional medicines. Medical marijuana is just a typical marijuana plant that is processed to get the fundamental composition of cannabinoids, which is necessary to synthesize the product to be in use.
Countries in North America have legalized the use and cultivation of medical cannabis. For instance, in 2012, Uruguay became the first country in the world to legalize the recreational use of cannabis. Similarly, in 2014, Brazil authorized the use of medical cannabis, and in 2016, it approved the import of medications based on CBD oil and products made from THC and marijuana flowers.
In 2017, Peru approved a law regulating the medicinal and therapeutic use of cannabis and its derivatives. In 2018, the Government of Canada passed the Cannabis Act, which created a strict legal framework for controlling the production, distribution, sale, and possession of cannabis across Canada. In the US, as of February 2022, marijuana was legalized in 37 states and the District of Columbia. In the past few years, Mexico, Luxembourg, and Lesotho, among others, have joined the list of countries to legalize the use of marijuana for medical applications.
However, despite widespread legalization of the use of cannabis, its legal cultivation and production have earlier been mostly limited to developing countries. In September 2019, the Ministry of Commerce, Agriculture, and Fisheries of Jamaica announced a partnership with Harvard International Phytomedicines and Medical Cannabis Institute (HIPI) to conduct research on the pharmacological benefits of marijuana. At the same time, Jamaica aims to capitalize on this partnership and utilize this opportunity to grow and develop its national marijuana industry.
Market Dynamics
Drivers
- Increasing Approvals of Medical Marijuana Products
- Rising Acceptance of Medicinal Use of Marijuana in America
Restraints
- Illegal Use of Cannabis as Street Drug and Misconceptions Regarding Marijuana
Opportunities
- Increase in Job Opportunities in Marijuana Industry
Future Trends
- Widespread Distribution of Medical Marijuana
Companies Mentioned
- Aphria, Inc.
- Canopy Growth Corporation
- CanaQuest Medical Corporation
- GW Pharmaceuticals
- Organigram Holdings Inc.
- VIVO Cannabis Inc
- Panaxia Pharmaceutical Industries Ltd
- Phoena Holdings Inc.
- Emerald Health Therapeutics Inc.
- MARICANN INC
For more information about this report visit
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
DUBLIN--(BUSINESS WIRE)--The "Medical Marijuana Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Application, Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering.
都柏林--(美國商業資訊)-「到 2028 年的醫用大麻市場預測-COVID-19 對產品、應用、分銷渠道和地理位置的影響和全球分析」報告已添加到 市場研究 提供。
The medical marijuana market was valued at US$ 11,706.50 million in 2021 and is likely to reach value of US$ 40,027.59 million by 2028; it is estimated to grow at a CAGR of 19.2% from 2022 to 2028.
在 2021 年,醫用大麻市場的價值為 11,706.50 萬美元,到 2028 年可能會達到 40,027.59 億美元的價值;據估計,從 2022 年到 2028 年,複合年增長率將達到 19.2% 的複合年增長率。
The report highlights trends prevailing in the market and factors driving the medical marijuana market. The market growth is attributed to increasing approvals of medical marijuana products and rising acceptance of the medicinal use of marijuana. However, the illegal use of cannabis as a street drug and misconceptions regarding marijuana limit the market growth.
該報告重點介紹了市場上普遍的趨勢以及推動醫用大麻市場的因素。市場增長歸因於醫用大麻產品的批准日益增加以及對大麻藥用途的接受程度不斷提高。但是,非法使用大麻作為街頭毒品和對大麻的誤解限制了市場增長。
Medical marijuana is in its introduction stage in the medical health industry. It is a potent product accepted globally, where Chinese medicines are already being manufactured using these plants, and that too with a long history associated. Medical marijuana remains a significant influence in the healthcare industry to treat cases that are not entirely advisable with traditional medicines. Medical marijuana is just a typical marijuana plant that is processed to get the fundamental composition of cannabinoids, which is necessary to synthesize the product to be in use.
醫用大麻正處於醫療衛生行業的引進階段。它是一種全球接受的有效產品,中藥已經使用這些植物製造,而且歷史悠久。醫用大麻在醫療保健行業對治療不完全不建議使用傳統藥物的病例仍然具有重大影響。醫用大麻只是一種典型的大麻植物,經過加工以獲得大麻素的基本成分,這對於合成要使用的產品是必要的。
Countries in North America have legalized the use and cultivation of medical cannabis. For instance, in 2012, Uruguay became the first country in the world to legalize the recreational use of cannabis. Similarly, in 2014, Brazil authorized the use of medical cannabis, and in 2016, it approved the import of medications based on CBD oil and products made from THC and marijuana flowers.
北美國家已將醫用大麻的使用和種植合法化。例如,在 2012 年,烏拉圭成為世界上第一個將大麻娛樂用途合法化的國家。同樣,在 2014 年,巴西授權使用醫用大麻,並在 2016 年,它批准進口基於 CBD 油和由 THC 和大麻花製成的產品的藥物。
In 2017, Peru approved a law regulating the medicinal and therapeutic use of cannabis and its derivatives. In 2018, the Government of Canada passed the Cannabis Act, which created a strict legal framework for controlling the production, distribution, sale, and possession of cannabis across Canada. In the US, as of February 2022, marijuana was legalized in 37 states and the District of Columbia. In the past few years, Mexico, Luxembourg, and Lesotho, among others, have joined the list of countries to legalize the use of marijuana for medical applications.
2017 年,秘魯批准了一項法律,規範大麻及其衍生物的藥用和治療用途。2018 年,加拿大政府通過了《大麻法》,為控制加拿大各地大麻的生產、分銷、銷售和擁有制定了嚴格的法律框架。在美國,截至 2022 年 2 月,大麻在 37 個州和哥倫比亞特區合法化。在過去的幾年中,墨西哥,盧森堡和萊索托(Lesotho)加入了國家列表,以使大麻用於醫療應用合法化。
However, despite widespread legalization of the use of cannabis, its legal cultivation and production have earlier been mostly limited to developing countries. In September 2019, the Ministry of Commerce, Agriculture, and Fisheries of Jamaica announced a partnership with Harvard International Phytomedicines and Medical Cannabis Institute (HIPI) to conduct research on the pharmacological benefits of marijuana. At the same time, Jamaica aims to capitalize on this partnership and utilize this opportunity to grow and develop its national marijuana industry.
但是,儘管使用大麻的普遍合法化,但其合法種植和生產早些時候主要局限於發展中國家。2019 年 9 月,牙買加商務農業和漁業部宣布與哈佛國際植物藥物和醫學大麻研究所(HIPI)建立合作夥伴關係,對大麻的藥理效益進行研究。與此同時,牙買加的目標是利用這一合作夥伴關係,並利用這個機會來發展和發展其國家大麻產業。
Market Dynamics
市場動態
Drivers
驅動
- Increasing Approvals of Medical Marijuana Products
- Rising Acceptance of Medicinal Use of Marijuana in America
- 增加醫用大麻產品的批准
- 美國對大麻藥用途的接受程度日益上升
Restraints
拘束
- Illegal Use of Cannabis as Street Drug and Misconceptions Regarding Marijuana
- 非法使用大麻作為街頭毒品和對大麻的誤解
Opportunities
機會
- Increase in Job Opportunities in Marijuana Industry
- 大麻行業的就業機會增加
Future Trends
未來趨勢
- Widespread Distribution of Medical Marijuana
- 醫用大麻的廣泛分佈
Companies Mentioned
提及的公司
- Aphria, Inc.
- Canopy Growth Corporation
- CanaQuest Medical Corporation
- GW Pharmaceuticals
- Organigram Holdings Inc.
- VIVO Cannabis Inc
- Panaxia Pharmaceutical Industries Ltd
- Phoena Holdings Inc.
- Emerald Health Therapeutics Inc.
- MARICANN INC
- 阿芙里亞, 公司
- 冠層增長公司
- 凱亞奎斯特醫療公司
- 毛重制药
- 有機金控股股份有限公司
- 活体大麻公司
- 泛夏製藥實業有限公司
- 菲娜控股有限公司
- 翡翠健康治療公司
- 馬里安公司
For more information about this report visit
有關此報告的更多信息,請訪問
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
市場研究
勞拉·伍德, 高級新聞經理
press@researchandmarkets.com
有關環球經濟部辦公時間,請致電 1-917-300-0470
對於美國/可以免付費電話致電 1-800-526-8630
如需格林威治標準時間辦公時間,請致電 353-1-416-8900
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧